SEATTLE--(BUSINESS WIRE)--May 6, 2019--
Omeros Corporation (NASDAQ: OMER), today announced that the company will
issue its first quarter 2019 financial results for the period ended
March 31, 2019, on Thursday, May 9, 2019, after the market closes.
Omeros management will host a conference call and webcast that day at
4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial
results as well as recent developments and highlights.
Conference Call Details
To access the live conference call via phone, please dial (844) 831-4029
from the United States and Canada or (920) 663-6278 internationally. The
participant passcode is 4095776. Please dial in approximately 10 minutes
prior to the start of the call. A telephone replay will be available for
one week following the call and may be accessed by dialing (855)
859-2056 from the United States and Canada or (404) 537-3406
internationally. The replay passcode is 4095776.
To access the live and subsequently archived webcast of the conference
call, go to Omeros’ website at www.omeros.com
and select “Events” under the Investors section of the website. Please
connect to the website at least 15 minutes prior to the call to allow
for any software download that may be necessary.
About Omeros Corporation
Omeros is a commercial-stage biopharmaceutical company committed to
discovering, developing and commercializing small-molecule and protein
therapeutics for large-market as well as orphan indications targeting
inflammation, complement-mediated diseases, disorders of the central
nervous system and immune-related diseases, including cancers. The
company’s drug product OMIDRIA® (phenylephrine and ketorolac intraocular
solution) 1% / 0.3% is marketed for use during cataract surgery or
intraocular lens (IOL) replacement to maintain pupil size by preventing
intraoperative miosis (pupil constriction) and to reduce postoperative
ocular pain. In the European Union, the European Commission has approved
OMIDRIA for use in cataract surgery and other IOL replacement procedures
to maintain mydriasis (pupil dilation), prevent miosis (pupil
constriction), and to reduce postoperative eye pain. Omeros has multiple
Phase 3 and Phase 2 clinical-stage development programs focused on:
complement-associated thrombotic microangiopathies; complement-mediated
glomerulonephropathies; cognitive impairment; and addictive and
compulsive disorders. In addition, Omeros has a diverse group of
preclinical programs and a proprietary G protein-coupled receptor (GPCR)
platform through which it controls 54 new GPCR drug targets and
corresponding compounds, a number of which are in preclinical
development. The company also exclusively possesses a novel
antibody-generating platform.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190506005816/en/
Source: Omeros Corporation
Jennifer Cook Williams
Cook Williams Communications, Inc.
Investor
and Media Relations
360.668.3701
